Takeda Yakuhin Kogyo KK

Latest Results (07.08.2024):

Revenue Growth

Takeda Yakuhin Kogyo KK reported a revenue of JPY 1,208.0 billion for the three-month period ended June 30, 2024, marking a 14.1% increase compared to the same period in the previous year. This growth was driven by favorable foreign exchange rates and strong performance in Plasma-Derived Therapies, Gastroenterology, Oncology, Rare Diseases, and Vaccines, partially offset by a decline in Neuroscience.

Operating Profit

For the three-month period ended June 30, 2024, Takeda Yakuhin Kogyo KK's operating profit was JPY 166.3 billion, a slight decrease of 1.3% from the previous year. This decline was primarily due to increased costs in sales, general and administrative expenses, and research and development expenses.

Net Profit

Takeda Yakuhin Kogyo KK achieved a net profit of JPY 95.3 billion for the three-month period ended June 30, 2024, representing a 6.6% increase from the same period in the previous year. This improvement was supported by a reduction in finance expenses and a favorable tax environment.

Core Operating Profit

The core operating profit for Takeda Yakuhin Kogyo KK during the three-month period ended June 30, 2024, was JPY 382.3 billion, reflecting a significant 17.1% increase compared to the same period last year. This growth underscores the company's strong operational performance and strategic focus on high-growth areas.

Dividends

Takeda Yakuhin Kogyo KK announced an annual dividend of JPY 196.00 per share for the fiscal year ending March 31, 2025, up from JPY 188.00 per share in the previous fiscal year. This increase in dividends reflects the company's commitment to returning value to its shareholders.